NASDAQ NMS - GLOBAL MARKET · CGEM
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Cullinan Therapeutics Inc

Cullinan Therapeutics Inc

Biotechnology
$21.68
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Earnings absence reason unknown
CGEM
Cullinan Therapeutics Inc
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CGEM moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CGEM catalysts
About Cullinan Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2021
Employees
109
Country
US

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$21.68
Last session
Day high
$21.68
Last session
Day low
$21.68
Last session
Previous close
$21.68
52W high
$22.52
-3.73% from high
52W low
$5.75
95% of range
Market cap
$1.4B
Beta
1.05
Shares out
64.4M
Avg volume
637.9K
VWAP
$21.68
Last session
Price history computed in-house
1W
+5.29%
1M
+26.78%
3M
+40.23%
1Y
+164.71%
YTD
+109.47%
SMA 50 $17.76 · above
SMA 200 $13.90 · above
52W position 95%

CGEM overview

Veridion Score
65
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CGEM.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CGEM Form 4 filings
Public disclosures

Congress activity in CGEM

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CGEM in the cached public ledger.

Federal contracts

CGEM contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CGEM in this window.
Lobbying spend

CGEM lobbying filings, year to date.

Registered lobbying filings matched to Cullinan Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CGEM in this window.
Loading news for CGEM
Analyst ratings
Sovereign unlock shows live analyst consensus for CGEM.
Options
Sovereign unlock shows live options positioning for CGEM.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.